Lenalidomide Capsule
Product Images NDC 70710-1031
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Lenalidomide (NDC 70710-1031). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Zydus Pharmaceuticals Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image (6077738e 3c5b 49de Bb89 E9d34e166c9c 02)
Image (6077738e 3c5b 49de Bb89 E9d34e166c9c 03)
Image (6077738e 3c5b 49de Bb89 E9d34e166c9c 06)
This appears to be a graph or table showing the proportion of subjects at different percentages (100%, 75%, 50%, and 25%) and the time to progression for two treatments (Lenalidomide/Dex and Placebo/Dex). The R value and confidence interval are also given, as well as a p-value. No further context or information is available in the text.*
Image (6077738e 3c5b 49de Bb89 E9d34e166c9c 07)
The given text represents a table showing the proportion of subjects in a study along with statistical values such as R (95% confidence interval) and Log Rank p value. There are two treatments mentioned as Lenalidomide/Dex and Placebo/Dex, and a graphical representation of time to progression (months) is also given.*
Label (6077738e 3c5b 49de Bb89 E9d34e166c9c 08)
Label (6077738e 3c5b 49de Bb89 E9d34e166c9c 09)
Label (6077738e 3c5b 49de Bb89 E9d34e166c9c 10)
Label (6077738e 3c5b 49de Bb89 E9d34e166c9c 11)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.